Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term adverse effects. Found 219 abstracts

no pagination
O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol. 2001 May;19(9):2413-21.
Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK, Schinella RA, Davis TE. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol. 2001 Feb;24(1):43-6.
Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet (London, England). 2001 Feb 10;357(9254):444-5.
Sasson AR, Watson JC, Sigurdson ER. Hepatic artery infusional chemotherapy for colorectal liver metastases. Cancer Treat Res. 2001 Jan;109:279-98.
Slingluff CL, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001 Oct;7(10):3012-24.
Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer. 2001 Nov 15;92(10):2639-47.
Treat J, Damjanov N, Huang C, Zrada S, Rahman A. Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology (Huntingt). 2001 May;15(5 Suppl 7):44-8.
von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res. 2001 May;7(5):1181-91.
Baselli EC, Greenberg RE. Intravesical therapy for superficial bladder cancer. Oncology (Huntingt). 2000 May;14(5):719-29; discussion 729-31, 734, 737.
Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Jun;77(3):446-9.
Dresler CM, Fratelli C, Babb J, Everley L, Evans AA, Clapper ML. Gender differences in genetic susceptibility for lung cancer. Lung Cancer. 2000 Dec;30(3):153-60.
Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M, Gallo JM. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res. 2000 Aug;6(8):3071-80.
Langer CJ, McAleer CA, Bonjo CA, Litwin S, Millenson M, Kosierowski R, Blankstein K, Alexander R, Ozols RF. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC). Eur J Cancer. 2000 Jan;36(2):183-93.
Schilder RJ, Blessing JA, Morgan M, Mangan CE, Rader JS. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol. 2000 Feb;76(2):204-7.
Schwartz AL, Nail LM, Chen S, Meek P, Barsevick AM, King ME, Jones LS. Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest. 2000 Jan;18(1):11-9.
Hudes GR, Lipsitz S, Grem J, Morrisey M, Weiner L, Kugler JW, Benson A. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292). Cancer. 1999 Jan 15;85(2):290-4.
Ross EA, Moore D. Modeling clustered, discrete, or grouped time survival data with covariates. Biometrics. 1999 Sep;55(3):813-9.
Weiner LM, Alpaugh RK, von Mehren M. Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins. Cancer immunology, immunotherapy : CII. 1997 Nov;45(3-4):190-2.
O'Dwyer PJ, Laub PB, DeMaria D, Qian M, Reilly D, Giantonio B, Johnston AL, Wu EY, Bauman L, Clendeninn NJ, Gallo JM. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clin Cancer Res. 1996 Oct;2(10):1685-92.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term adverse effects

Human adverse effects Female drug therapy US Gov't Support-PHS Middle Age therapeutic use Aged Male Adult Non-US Gov't Support administration & dosage pathology Antineoplastic Combined Chemotherapy Protocols effects adverse analogs & derivatives Neoplasms Antineoplastic Agents 80 and over Aged metabolism Lung Neoplasms Survival Analysis chemically induced Treatment Outcome drug effects immunology Fluorouracil Intravenous Infusions Survival Rate Paclitaxel Risk Factors Drug Administration Schedule Oral Administration Cancer Vaccines Cisplatin pharmacokinetics Area Under Curve Leucovorin Deoxycytidine Prognosis Breast Neoplasms US Gov't Support-Non-PHS Local Neoplasm Recurrence mortality Non-Small-Cell Lung Carcinoma use Disease-Free Survival Cohort Studies dosage Colorectal Neoplasms Fatigue Cervix Neoplasms administration & prevention & control Immunologic Adjuvants Adjuvant Chemotherapy genetics Drug Dose-Response Relationship Squamous Cell Carcinoma Neoplasm Metastasis therapeutic Genetic Predisposition to Disease Population Genetics CD4-Positive T-Lymphocytes Chromosome Aberrations Intravesical Administration Genotype blood Disease Progression Cytotoxic T-Lymphocytes surgery Cytotoxins Mycobacterium bovis Drug Delivery Systems Transitional Cell Carcinoma Peptide Fragments secretion Cell Line Mononuclear Leukocytes Agranulocytosis Bladder Neoplasms Proportional Hazards Models Liver Neoplasms Pain Inbreeding Metabolic Clearance Rate Interferon Alfa-2a IgG Receptors Follow-Up Studies Intra-Arterial Infusions Immunity biosynthesis cytology Analysis of Variance Th1 Cells Amino Acid Sequence methods physiopathology Statistical Data Interpretation Randomized Controlled Trials Radiotherapy Immunoglobulin G Cell Division statistics & numerical data Pedigree Antineoplastic Antibiotics Lymph Nodes Antineoplastic Antimetabolites Biometry Adolescent Case-Control Studies Phytogenic Antineoplastic Agents Cultured Tumor Cells Bilirubin Residual Neoplasm Stomach Neoplasms Superantigens Bispecific Antibodies T-Lymphocytes Phosphonoacetic Acid Interferons Mesothelioma Skin Diseases Cytochrome P-450 CYP1A1 radiotherapy HLA-A2 Antigen Light Coagulation Carboplatin Anticarcinogenic Agents Turkey Cytokines Dominant Genes urine Polymorphism (Genetics) Multiple Drug Resistance Chromosome Disorders Linear Models Neoplasm Proteins Interferon-alpha Alanine Transaminase Biopsy Aspartic Acid Cluster Analysis Likelihood Functions Patient Selection Phase I Clinical Trials Doxorubicin Mitomycin Proto-Oncogene Protein p21(ras)
Last updated on Friday, January 03, 2020